Antidepressant Medication Recalled Due to Potential Carcinogen Levels

Nearly 370,000 bottles of duloxetine, a generic antidepressant, have been recalled by Breckenridge Pharmaceuticals. The recall is due to levels of N-nitroso-duloxetine impurity exceeding FDA safety standards, which is suspected of causing cancer. The FDA has categorized this as a Class II recall, indicating that while temporary health problems are possible, serious long-term consequences are unlikely.